LIV Emles at Home ETF

Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced today it has received its unique CAS Registry Number for the chemical substance in its Alzheimer's drug SP-233. CAS Registry Numbers are used in reference works, databases, and regulatory compliance documents, to identify substances without the ambiguity of chemical nomenclature. -0- *T Substance ID: Caprospinol CAS No.: 873956-96-8 *T Dr. Greeson, CEO of Samaritan Pharmaceuticals, stated, "We are completely excited about SP-233 (Caprospinol) as a totally new approach to treat Alzheimer's disease." Dr. Greeson continued, "We have been aggressively pushing to file an investigational new drug (IND) application for Caprospinol and this is one of the many milestones we have had to achieve to get there." Samaritan Pharmaceuticals: "We LIV....to Save Lives." Samaritan Pharmaceuticals is a drug development company driven to discover, develop, and commercialize, innovative therapeutics for AIDS, Alzheimer's, Cancer and Heart disease. Samaritan, in collaboration with Georgetown University, is advancing eight promising compounds, out of its rich pipeline of 250 possible drug candidates, all of which have the potential to create revenue-generating opportunities. Additional information is at www.samaritanpharma.com. Disclaimer The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 15, 2005. The company undertakes no duty to update forward-looking statements.